Navigation Links
Alzheimer's disease in mice alleviated promising therapeutic approach for humans
Date:11/25/2012

Alzheimer's disease is one of the most common causes of dementia. In Germany and Switzerland alone, around 1.5 million people are affected, and forecasts predict a doubling of the number of patients worldwide within the next 20 years. The accumulation of particular abnormal proteins, including amyloid- (Aβ) among others, in patients' brains plays a central role in this disease. Prof. Frank Heppner from the Department of Neuropathology at Charit and his colleague Prof. Burkhard Becher from the Institute for Experimental Immunology at the University of Zurich were able to show that turning off particular cytokines (immune system signal transmitters) reduced the Alzheimer's typical amyloid- deposits in mice with the disease. As a result, the strongest effects were demonstrated after reducing amyloid- by approximately 65 percent, when the immune molecule p40 was affected, which is a component of the cytokines interleukin (IL)-12 and -23.

Relevant for human therapy

Follow-up experiments also relevant for humans showed that substantial improvements in behavioral testing resulted when mice were given the antibody blocking the immune molecule p40. This effect was also achieved when the mice were already showing symptoms of the disease. Based on the current study by Prof. Heppner's and Prof. Becher's team, the level of p40 molecules is higher in Alzheimer's patients' brain fluid, which is in agreement with a recently published study by American colleagues demonstrating increased p40 levels in blood plasma of subjects with Alzheimer's disease, thus showing obvious relevance for human therapy.

The significance of the immune system in Alzheimer's research is the focus of current efforts. Prof. Heppner and Prof. Becher suspect that cytokines IL-12 and IL-23 themselves are not causative in the pathology, and that the mechanism of the immune molecule p40 in Alzheimer's requires additional clarification. However, they are convinced that the results of their six-years of research work justify the step toward clinical studies in humans, for which they plan to collaborate with a suitable industrial partner.

IIn the context of other illnesses, such as psoriasis, a medication that suppresses p40 in humans has already been applied. "Based on the safety data in patients," comment Profs. Heppner and Becher, "clinical studies could now be implemented without delay. Now, the goal is to bring the new therapeutic approach to Alzheimer patients quickly."


'/>"/>
Contact: Prof. Burkhard Becher
becher@immunology.uzh.ch
41-446-353-703
University of Zurich
Source:Eurekalert  

Related biology news :

1. Short DNA strands in the genome may be key to understanding human cognition and diseases
2. Discovery of molecular pathway of Alzheimers disease reveals new drug targets
3. Scripps Research Institute team identifies a potential cause of Parkinsons disease
4. Yeast protein breaks up amyloid fibrils and disease protein clumps differently
5. Scientists question the designation of some emerging diseases
6. Call for global monitoring of infectious diseases in dogs and cats
7. Cells from skin create model of blinding eye disease
8. New drug target found for cystic fibrosis lung disease
9. Researchers test solution to fungal disease of ash trees
10. Daily multivitamin use does not reduce cardiovascular disease risk in men
11. Berkeley Lab scientists help develop promising therapy for Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Alzheimer's disease in mice alleviated promising therapeutic approach for humans
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
(Date:3/15/2016)... 2016 --> --> ... Market Research "Digital Door Lock Systems Market - Global Industry ... the global digital door lock systems market in terms of ... is forecast to grow at a CAGR of 31.8% during ... medium enterprises (MSMEs) across the world and high industrial activity ...
(Date:3/11/2016)... , March 11, 2016 http://www.apimages.com ) - ... reference: Picture is available at AP Images ( http://www.apimages.com ) - ... will be used to produce the new refugee identity cards. DERMALOG ... innovations, at CeBIT in Hanover next week.   ... DERMALOG will be used to produce the new refugee identity cards. ...
Breaking Biology News(10 mins):
(Date:5/24/2016)... Rockville, Maryland (PRWEB) , ... May 24, 2016 ... ... introduction of a newly re-branded identity. The new Media Cybernetics corporate branding reflects ... the world of imaging and image analysis. The re-branding components include a crisp, ...
(Date:5/23/2016)... LONDON , May 23, 2016 ... Boost Efficiency by 40% - Frontage Implement a Single ... Enforce Quality, Compliance and Traceability Within the Bioanalytical lab ... the United States and China ... deployed across its laboratory facilities. In addition to serving as the ...
(Date:5/20/2016)... ... 2016 , ... Kablooe Design, a leading provider of product design and development ... of the business. “We have worked hard to build long-term relationships,” says President and ... and honor of serving their product design and development needs through the years.” , ...
(Date:5/19/2016)... May 19, 2016 There is ... recover given the relentless pressures in pricing and lack ... the investors circle though - numerous opportunities are up ... today,s session, ActiveWallSt.com,s presents four names in this sector: ... Pharmaceuticals Inc. (NASDAQ: VTAE ), Anthera Pharmaceuticals ...
Breaking Biology Technology: